Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Darovasertib - IDEAYA Biosciences

Next Previous
Drug Profile

Darovasertib - IDEAYA Biosciences

Alternative Names: IDE 196; LXS-196; NVP-LXS-196

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer IDEAYA Biosciences; Novartis; St Vincents Hospital, Sydney
  • Class Amides; Amines; Antineoplastics; Fluorinated hydrocarbons; Piperidines; Pyrazines; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Uveal melanoma
  • Phase II Colorectal cancer; Malignant melanoma; Solid tumours
  • Preclinical Nevus
  • No development reported Neurological disorders

Most Recent Events

  • 31 Mar 2025 In March 2025, IDEAYA Biosciences plans to initiate a phase III trial in Uveal Melanoma (Neoadjuvant therapy) in the first half of 2025
  • 31 Mar 2025 Darovasertib - IDEAYA Biosciences receives Breakthrough Therapy status for Uveal melanoma (Neoadjuvant therapy) in USA
  • 04 Nov 2024 IDEAYA Biosciences plans a potential registration-enabling trial in the first half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top